Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 10/20 | 0.54 |
| ▸ | EDNRB | P24530 | 9/20 | 0.54 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237393 | 0.78 | KEAP1 (0.50) | EDNRAEDNRB | |
| SCHEMBL8694517 | 0.75 | EDNRA (0.56) | EDNRAEDNRBFBP1CASP1 | |
| SCHEMBL8350452 | 0.74 | EDNRA (0.54) | EDNRAEDNRBFBP1CASP1 | |
| SCHEMBL4617033 | 0.73 | ALDH1A1 (0.54) | EDNRAEDNRBCASP1 | |
| SCHEMBL7404641 | 0.72 | SCN9A (0.53) | EDNRAEDNRBFBP1 | |
| SCHEMBL15668311 | 0.72 | CASP1 (0.51) | EDNRAEDNRBACLYFBP1CASP1 | |
| SCHEMBL7243371 | 0.71 | EDNRA (0.54) | EDNRAEDNRBFBP1 | |
| SCHEMBL6151288 | 0.70 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL7557151 | 0.70 | EDNRA (0.64) | EDNRAEDNRB | |
| SCHEMBL1767981 | 0.70 | CA2 (0.58) | EDNRAEDNRBACLYFBP1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1636994-B | Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby | ENCYSIVE PHARMACEUTICALS INC | 2010-05-12 | — | — | CN | disclosed |
| CN-100558724-C | Adjust active sulphonamide of endothelium peptide and derivative thereof | ANSEHIV PHARMACEUTICAL CORP (US) | 2009-11-11 | — | — | CN | disclosed |
| CN-1215069-C | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1636994-A | Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1179961-C | Sulfonamides for the treatment of endothelin mediated diseases | ��ɪϣ����ҩ��˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1530366-A | Sulphonic acid amide for regulating bast peptide activity and derivative thereof | ��ɪϣ����ҩ��˾ | 2004-09-22 | — | — | CN | disclosed |
| CN-1130355-C | Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 2003-12-10 | — | — | CN | disclosed |
| US-6541498-B2 | Antiinflammatory agents, antiasthmatics | TEXAS BIOTECHNOLOGY | 2003-04-01 | — | — | US | disclosed |
| US-6376523-B1 | HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE | TEXAS BIOTECHNOLOGY CORPORATION | 2002-04-23 | — | — | US | disclosed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| CN-1253560-A | Sulfonamides for the treatment of endothelin mediated diseases | TEXA BIOTECHNOLOGY CORP (US) | 2000-05-17 | — | — | CN | disclosed |
| US-6030991-A | ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS | TEXAS BIOTECHNOLOGY CORP. (US) | 2000-02-29 | — | — | US | disclosed |
| CN-1231664-A | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | disclosed |
| CN-1184470-A | Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 1998-06-10 | — | — | CN | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5464853-A | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | IMMUNOPHARMACEUTICS, INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5464853-A | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | IMMUNOPHARMACEUTICS, INC. (US) | 1995-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | EDNRB, EDNRA, ECE1 | EDNRA 2/4885EDNRB 1/4885ACLY 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.